Stocks › VKTX

Viking Therapeutics, Inc.

VKTX·Nasdaq·United States United States·USD
$24.77
-1.07 (-4.14%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
VKTX
Viking Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
VKTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of VKTX by members of U.S. Congress · 0 on record

No congressional trades in VKTX on record.

Whale Activity

Position changes in VKTX reported for 2026-09-30 by 505 institutional filers
Increased: 156New: 74Held: 66Decreased: 119Closed: 63No prior filing: 27
  • Increased156
  • New74
  • Held66
  • Decreased119
  • Closed63
  • No prior filing27
FilerSharesValueChange
FMR LLC9.8M$321.0Mincreased
BlackRock, Inc.6.2M$201.0Mdecreased
STATE STREET CORP5.5M$180.8Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC5.4M$175.9Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC4.7M$153.8Mincreased
MORGAN STANLEY3.6M$116.7Mincreased
TWO SIGMA INVESTMENTS, LP2.4M$78.3Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.2M$71.8Mincreased
CITADEL ADVISORS LLC1.9M$60.6Mincreased
AMERICAN CENTURY COMPANIES INC1.6M$53.1Mdecreased
AQR CAPITAL MANAGEMENT LLC1.3M$41.7Mincreased
UBS Group AG1.1M$34.8Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by VKTX insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -297.8K2025 Q12025 Q2: 02025 Q22025 Q3: -35.4K2025 Q32025 Q4: -111.4K2025 Q42026 Q1: -360.3K2026 Q12026 Q2: 02026 Q22026 Q3: -188.0K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

344 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Kelly-Gemmell Dorothy ElizabethDirector Grant / award +6,333 $0.00 $0 Aug 1, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Sale −148.5K $33.32 $4.9M Jul 29, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Sale −21.2K $33.47 $710K Jul 29, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Sale −18.2K $33.47 $610K Jul 29, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Grant / award +221.7K $0.00 $0 Jul 28, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Grant / award +31.7K $0.00 $0 Jul 28, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Grant / award +31.7K $0.00 $0 Jul 28, 2026 Form 4 ↗
Aubuchon Neil WilliamChief Commercial Officer Purchase +4,475 $33.50 $150K Mar 10, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Sale −1,500 $32.09 $48K Jan 5, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Sale −10.3K $34.24 $353K Jan 5, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Sale −13.9K $33.38 $464K Jan 5, 2026 Form 4 ↗
ZANTE GREGChief Financial Officer Sale −32.0K $32.30 $1.0M Jan 5, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Sale −1,600 $35.07 $56K Jan 5, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Sale −10.5K $34.22 $359K Jan 5, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Sale −13.6K $33.37 $454K Jan 5, 2026 Form 4 ↗
Mancini MariannaChief Operating Officer Sale −32.0K $32.29 $1.0M Jan 5, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Sale −6,400 $35.07 $224K Jan 5, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Sale −41.3K $34.22 $1.4M Jan 5, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Sale −53.3K $33.38 $1.8M Jan 5, 2026 Form 4 ↗
Lian BrianPresident & CEO · Director Sale −132.5K $32.29 $4.3M Jan 5, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding VKTX · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
3.6M$140.0M1.30%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.5M$136.5M0.01%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
2.5M$98.6M0.05%Jun 30, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.5M$56.9M0.12%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.3M$52.0M0.05%Jun 30, 2026
Heritage Fund
American Century Mutual Funds, Inc.
1.3M$42.3M0.80%Jul 31, 2026
Fidelity Advisor Growth Opportunities Fund
Fidelity Advisor Series I
1.1M$34.8M0.10%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
569.2K$18.7M0.05%Aug 31, 2026
iShares Russell Mid-Cap ETF
iShares Trust
467.2K$18.2M0.03%Jun 30, 2026
Schwab U.S. Small-Cap ETF
SCHWAB STRATEGIC TRUST
553.4K$18.1M0.08%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list VKTX's shares (CUSIP 92686J106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 9.5M shares7.7%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 9.5M shares7.7%
    Nov 5, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Viking Therapeutics, Inc. as client

No lobbying filings found naming Viking Therapeutics, Inc. as the client.

Government Contracts

Federal awards to Viking Therapeutics, Inc. · USAspending

No federal contract awards found for Viking Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Viking Therapeutics, Inc.

No USPTO patent applications found for Viking Therapeutics, Inc..

Annual Financials

From VKTX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$0$0$0$0$0
Operating income-$393.3M-$150.9M-$100.8M-$70.4M-$55.7M
Net income-$359.6M-$110.0M-$85.9M-$68.9M-$55.0M
Diluted EPS-$3.19-$1.01-$0.91-$0.90-$0.71
Operating cash flow-$278.7M-$87.8M-$73.4M-$48.4M-$47.6M
Cash and equivalents$165.8M$26.7M$55.5M$36.6M$26.4M
Total assets$715.7M$908.3M$368.5M$168.5M$210.7M
Total liabilities$76.7M$28.0M$20.1M$23.2M$8.8M
Shareholders' equity$639.1M$880.3M$348.4M$145.3M$201.9M

As Viking Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in VKTX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsOct 28, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationSep 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 22, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 9.01Shareholder voteMay 26, 2026
    EDGAR ↗

About Viking Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE